Cargando…

Ketamine as a therapeutic agent in major depressive disorder and posttraumatic stress disorder: Potential medicinal and deleterious effects

Major depressive disorder (MDD) and posttraumatic stress disorder (PTSD) are the most common causes of emotional distress that impair an individual's quality of life. MDD is a chronic mental illness that affects 300 million people across the world. Clinical manifestations of MDD include fatigue...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sachdeva, Bhuvi, Sachdeva, Punya, Ghosh, Shampa, Ahmad, Faizan, Sinha, Jitendra Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10528797/ https://www.ncbi.nlm.nih.gov/pubmed/37786516 http://dx.doi.org/10.1002/ibra.12094

Ejemplares similares

Chitosan Nanoparticles-Based Cancer Drug Delivery: Application and Challenges
por: Sachdeva, Bhuvi, et al.
Publicado: (2023)

Characterization of Comorbid Posttraumatic Stress Disorder and Major Depressive Disorder Using Ketamine as an Experimental Medicine Probe (†)
por: Albott, C. Sophia, et al.
Publicado: (2021)

Plausible Role of Stem Cell Types for Treating and Understanding the Pathophysiology of Depression
por: Sachdeva, Punya, et al.
Publicado: (2023)

Childhood Obesity: A Potential Key Factor in the Development of Glioblastoma Multiforme
por: Sachdeva, Punya, et al.
Publicado: (2022)

Potential natural products for the management of autism spectrum disorder
por: Sachdeva, Punya, et al.
Publicado: (2022)

A consolidated review on stem cell therapy for treatment and management of Alzheimer's disease
por: Ahmad, Faizan, et al.
Publicado: (2022)

Critical appraisal on mitochondrial dysfunction in Alzheimer’s disease
por: Ahmad, Faizan, et al.
Publicado: (2022)

Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder
por: Davis, Margaret T., et al.
Publicado: (2021)

Circadian dysfunction and Alzheimer's disease – An updated review
por: Ahmad, Faizan, et al.
Publicado: (2022)

Progeria: A rare genetic premature ageing disorder
por: Sinha, Jitendra Kumar, et al.
Publicado: (2014)

The Effect of Ketamine on Electrophysiological Connectivity in Major Depressive Disorder
por: Nugent, Allison C., et al.
Publicado: (2020)

Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives
por: Shin, Cheolmin, et al.
Publicado: (2020)

Nanotube breakthroughs: unveiling the potential of carbon nanotubes as a dual therapeutic arsenal for Alzheimer’s disease and brain tumors
por: Elsori, Deena, et al.
Publicado: (2023)

Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder
por: Rong, Carola, et al.
Publicado: (2018)

Modulation of the functional connectome in major depressive disorder by ketamine therapy
por: Sahib, Ashish K., et al.
Publicado: (2022)

Emergence of taurine as a therapeutic agent for neurological disorders
por: Jangra, Ashok, et al.
Publicado: (2023)

Analysis of the Deleterious Single-Nucleotide Polymorphisms Associated With Antidepressant Efficacy in Major Depressive Disorder
por: Xin, Juncai, et al.
Publicado: (2020)

Genetic evidence suggests posttraumatic stress disorder as a subtype of major depressive disorder
por: Zhang, Fuquan, et al.
Publicado: (2022)

Psychological trauma and the genetic overlap between posttraumatic stress disorder and major depressive disorder
por: Mundy, Jessica, et al.
Publicado: (2022)

The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence
por: Ragnhildstveit, Anya, et al.
Publicado: (2023)

Efficacy of different doses of ketamine as a bolus in major depressive disorder
por: Kheirkhah, Farzan, et al.
Publicado: (2018)

Could ketamine be the answer to treating treatment-resistant major depressive disorder?
por: Ramadan, Abdullah Mohammed, et al.
Publicado: (2020)

The role of major depression in neurocognitive functioning in patients with posttraumatic stress disorder
por: Nijdam, Mirjam J., et al.
Publicado: (2013)

Posttraumatic Stress Disorder Increases Sensitivity to Long Term Losses among Patients with Major Depressive Disorder
por: Engelmann, Jan B., et al.
Publicado: (2013)

Acute Ketamine Administration Corrects Abnormal Inflammatory Bone Markers in Major Depressive Disorder
por: Kadriu, Bashkim, et al.
Publicado: (2017)

The functional connectivity of the middle frontal cortex predicts ketamine’s outcome in major depressive disorder
por: Zhang, Fan, et al.
Publicado: (2022)

3525 Improvement in Suicidal Ideation after Repeated Ketamine Infusions: Relationship to Reductions in Symptoms of Posttraumatic Stress Disorder, Depression, and Pain
por: Albott, Cristina Sophia, et al.
Publicado: (2019)

Correction: Posttraumatic Stress Disorder Increases Sensitivity to Long Term Losses among Patients with Major Depressive Disorder
Publicado: (2014)

Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder
por: Murrough, J W, et al.
Publicado: (2015)

Effects of ketamine in electroconvulsive therapy for major depressive disorder: meta-analysis of randomised controlled trials
por: Li, Xiao-Mei, et al.
Publicado: (2020)

Functional connectivity of the amygdala and the antidepressant and antisuicidal effects of repeated ketamine infusions in major depressive disorder
por: Liu, Haiyan, et al.
Publicado: (2023)

Commentary on Cochrane review: “Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder”
por: Borentain, Stephane, et al.
Publicado: (2022)

Hemicrania Continua Headache in a Veteran with Posttraumatic Stress Disorder and Major Depressive Disorder without Traumatic Brain Injury
por: Kohrt, Brandon A., et al.
Publicado: (2012)

Transdiagnostic Symptom Subtypes to Predict Response to Therapeutic Transcranial Magnetic Stimulation in Major Depressive Disorder and Posttraumatic Stress Disorder
por: Cosmo, Camila, et al.
Publicado: (2022)

Aberrant brain entropy in posttraumatic stress disorder comorbid with major depressive disorder during the coronavirus disease 2019 pandemic
por: Fu, Shishun, et al.
Publicado: (2023)

Nicotine Use and Metabotropic Glutamate Receptor 5 in Individuals With Major Depressive and Posttraumatic Stress Disorders
por: Baldassarri, Stephen R., et al.
Publicado: (2023)

The Study of Ketamine for Youth Depression (SKY-D): study protocol for a randomised controlled trial of low-dose ketamine for young people with major depressive disorder
por: Schwartz, Orli S., et al.
Publicado: (2023)

The need for rejuvenation of Indian biomedical journals
por: Ghosh, Shampa, et al.
Publicado: (2010)

The R-Stereoisomer of Ketamine as an Alternative for Ketamine for Treatment-resistant Major Depression
por: Hashimoto, Kenji
Publicado: (2014)

Characterizing emotional Stroop interference in posttraumatic stress disorder, major depression and anxiety disorders: A systematic review and meta-analysis
por: Joyal, Marilyne, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_neri302pm5i55at73h3lichue5